Quantitative analysis on the characteristics of targets with FDA approved drugs

Quantitative analysis on the characteristics of targets with FDA approved drugs

<p>Accumulated knowledge of genomic information, systems biology, and disease mechanisms provide an unprecedented opportunity to elucidate the genetic basis of diseases, and to discover new and novel therapeutic targets from the wealth of genomic data. With hundreds to a few thousand potential...

Full description

Bibliographic Details
Main Author:	Meena K. Sakharkar, Peng Li, Zhaowei Zhong, Kishore R. Sakharkar
Format:	Article
Language:	English
Published:	Ivyspring International Publisher 2008-01-01
Series:	International Journal of Biological Sciences
Online Access:	http://www.biolsci.org/v04p0015.htm

Similar Items

Hybrid-drug design targeting pseudomonas aeruginosa DHPS and DHFR
by: Jayaraman, Premkumar, et al.
Published: (2014)

Human genomic diversity, viral genomics and proteomics, as exemplified by human papillomaviruses and H5N1 influenza viruses
by: Sakharkar Meena K, et al.
Published: (2009-07-01)

Activity of Chitosans in combination with antibiotics in Pseudomonas aeruginosa
by: San Tin, Kishore R. Sakharkar, Chu Sing Lim, Meena K. Sakharkar
Published: (2009-01-01)

Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA
by: Lang Zheng, et al.
Published: (2024-02-01)

Biodegradation of low density polythene (LDPE) by pseudomonas species
by: Sakharkar, Kishore R., et al.
Published: (2013)

Alterations in Gene Pair Correlations as Potential Diagnostic Markers for Colon Cancer
by: Bonnie Yang Yang, et al.
Published: (2022-10-01)

Activity and interactions of antibiotic and phytochemical combinations against Pseudomonas aeruginosa in vitro
by: Premkumar Jayaraman, Meena K Sakharkar, Chu Sing Lim, Thean Hock Tang, Kishore R. Sakharkar
Published: (2010-01-01)

A combined computational-experimental analyses of selected metabolic enzymes in Pseudomonas species
by: Deepak Perumal, Chu Sing Lim, Vincent T.K. Chow, Kishore R. Sakharkar, Meena K. Sakharkar
Published: (2008-01-01)

Probing the mechanism of action (MOA) of Solanum nigrum Linn against breast cancer using network pharmacology and molecular docking
by: Yingying Song, et al.
Published: (2023-04-01)

Gallic Acid Potentiates the Antimicrobial Activity of Tulathromycin Against Two Key Bovine Respiratory Disease (BRD) Causing-Pathogens
by: Karthic Rajamanickam, et al.
Published: (2019-01-01)

A Novel Antimicrobial–Phytochemical Conjugate With Antimicrobial Activity Against Streptococcus uberis, Enterococcus faecium, and Enterococcus faecalis
by: Karthic Rajamanickam, et al.
Published: (2019-11-01)

Enhancing Drug Efficacy against Mastitis Pathogens—An In Vitro Pilot Study in <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i>
by: Karthic Rajamanickam, et al.
Published: (2020-11-01)

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
by: Jonas Cicenas, et al.
Published: (2021-02-01)

Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
by: Shigeto Nishikawa, et al.
Published: (2023-01-01)

Novel phytochemical antibiotic conjugates as multitarget inhibitors of pseudomononas aeruginosa GyrB/ParE and DHFR
by: Jayaraman, Premkumar, et al.
Published: (2014)

Genome SEGE: A database for 'intronless' genes in eukaryotic genomes
by: Sakharkar Meena, et al.
Published: (2004-06-01)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
by: Su Min Cho, et al.
Published: (2022-05-01)

Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs
by: Ha Yeong Choi, et al.
Published: (2023-09-01)

FDA-approved drugs in 2022: A brief outline
by: Haitham Ahmed Al-Madhagi
Published: (2023-03-01)

Effects of Sphingosine-1-Phosphate on Cell Viability, Differentiation, and Gene Expression of Adipocytes
by: Xiyuan Wu, et al.
Published: (2020-12-01)

Effects of adipocyte-conditioned cell culture media on S1P treatment of human triple-negative breast cancer cells
by: Xiyuan Wu, et al.
Published: (2023-01-01)

Effects of adipocyte-conditioned cell culture media on S1P treatment of human triple-negative breast cancer cells.
by: Xiyuan Wu, et al.
Published: (2023-01-01)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
by: Juliana T. W. Tong, et al.
Published: (2021-09-01)

Synthesis and clinical application of new drugs approved by FDA in 2022
by: Jing-Yi Zhang, et al.
Published: (2023-09-01)

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)
by: Ghulam Shabir, et al.
Published: (2023-08-01)

FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
by: Carla Rizzo, et al.
Published: (2023-04-01)

FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review
by: Aleksandra Sochacka-Ćwikła, et al.
Published: (2021-12-01)

Ebanga™: The most recent FDA-approved drug for treating Ebola
by: Elahe Taki, et al.
Published: (2023-03-01)

Computational and Experimental Drug Repurposing of FDA-Approved Compounds Targeting the Cannabinoid Receptor CB1
by: Emanuele Criscuolo, et al.
Published: (2023-12-01)

Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2
by: Hualou Liang, et al.
Published: (2021-05-01)

FDA Approvals of Biologics in 2022
by: Alexander C. Martins, et al.
Published: (2023-05-01)

FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights
by: Krakauer T
Published: (2017-05-01)

The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2024-01-01)

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2021-01-01)

The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2022-02-01)

The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2023-01-01)

Novel use of FDA-approved drugs identified by cluster analysis of behavioral profiles
by: Sara Tucker Edmister, et al.
Published: (2022-04-01)

The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2020-02-01)

The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2019-02-01)

The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2018-02-01)